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Abstract Fibroblast growth factor receptor (FGFR) sig-
naling is involved in multiple biological processes, including
cell proliferation, survival, differentiation, migration, and
apoptosis during embryonic development and adult tissue
homeostasis. Given its role in the activation of critical sig-
naling pathways, aberrant FGFR signaling has been impli-
cated in multiple cancer types. A comprehensive search of
PubMed and congress abstracts was conducted to identify
reports on FGFR pathway components in breast cancer. In
breast cancers, FGFR1 and FGFR4 gene amplification and
single nucleotide polymorphisms in FGFR2 and FGFR4
have been detected. Commonly, these FGFR aberrations and
gene amplifications lead to increased FGFR signaling and
have been linked with poor prognosis and resistance to breast
cancer treatments. Here, we review the role of FGFR sig-
naling and the impact of FGFR genetic amplifications/
aberrations on breast tumors. In addition, we summarize the
most recent preclinical and clinical data on FGFR-targeted
therapies in breast cancer. Finally, we highlight the ongoing
clinical trials of the FGFR-targeted agents dovitinib,
AZD4547, lucitanib, BGJ398, and JNJ-42756493, which are
selected for patients with FGFR pathway-amplified breast
cancer. Aberrant FGFR pathway amplification may drive
some breast cancers. Inhibition of FGFR signaling is being
explored in the clinic, and data from these trials may refine
our ability to select patients who would best respond to these
treatments.
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Role of FGFR signaling
The fibroblast growth factor receptor (FGFR) family comprises
four transmembrane tyrosine kinase receptors (FGFR1-4).
Each FGFR has an extracellular ligand-binding domain con-
taining three immunoglobulin (Ig)-like domains and an acidic
box, a single-pass transmembrane domain, and an intracellular
tyrosine kinase domain [1]. Twenty-two FGF ligands bind to
the second and third Ig-like domains of the different FGFRs and
their splice variants, creating ligand-binding specificity [2–4].
Ligand binding induces receptor dimerization, enabling
transphosphorylation of intracellular kinases, and phosphory-
lation of intracellular signaling proteins.
FGFR signaling is involved in cell proliferation, sur-
vival, differentiation, migration, and apoptosis during em-
bryonic development and adult tissue homeostasis [1].
Signaling is regulated in part by the spatial and temporal
expression patterns of the different ligands and receptors,
leading to distinct cell type-specific functions. For exam-
ple, during embryogenesis, FGFR signaling plays a key
role in the development of the nervous system, limbs,
midbrain, lungs, and mammary glands. In contrast, FGFR
signaling in the adult drives tissue repair, angiogenesis, and
inflammation.
FGFR genetic aberrations in breast cancer
Multiple genetic aberrations in FGFRs leading to increased
pathway activation have been identified in breast cancer. The
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most common aberration is FGFR1 gene amplification (one
of several putative oncogenes on 8p11-12), which is present
in 7.5–17 % of all breast cancer and in 16–27 % of luminal
B-type breast cancer (although variability in these numbers
is expected, given the different methods used to assess am-
plification) [5–13]. In addition to FGFR1 gene amplification,
elevated mRNA is detected in 22 % of tumor cell lines and
breast-tumor samples [14], and gene amplification is ro-
bustly associated with FGFR1 overexpression [7, 10, 13].
Amplification of other FGFRs has also been observed. For
example, amplification of FGFR2 (10q26) was identified in
4 % of triple-negative breast cancers (TNBCs) [15], and two
TNBC cell lines (SUM52PE, MFM223) with FGFR2 am-
plification showed constitutive activation of FGFR2. Inter-
estingly, survival of SUM52PE and MFM223 was dependent
on FGFR2 expression and tyrosine kinase activity. FGFR4
amplification has been detected in &10 % of breast cancer
samples and was associated with estrogen receptor (ER) and
progesterone receptor (PR) positivity and lymph node
metastases [16]. In a separate study, elevated FGFR4 mRNA
levels were detected in 32 % of breast cancer samples [14].
Single nucleotide polymorphisms (SNPs) have also been
detected in FGFR genes in breast tumors. For example, SNPs
were identified in FGFR2 intron 2 [17–22] and, in some
studies, were more common in ER-positive (ER?) tumors
[18, 22]. Intron 2 of FGFR2 contains putative transcription
factor binding sites, and one of the SNPs, rs2981578, in-
creased Oct-1/Runx2 and C/EBPb transcription factor
binding, which led to increased FGFR2 expression [21]. In
the transmembrane region of FGFR4, a SNP involving the
conversion of Gly to Arg was identified, and FGFR4Arg388-
expressing MDA-MB-231 mammary tumor cells showed
increased motility in comparison with cells expressing the
FGFR4Gly388 allele [23]. Additionally, introduction of the
FGFR4Arg388 allele in a transgenic mammary tumor model
induced more rapid tumor formation and progression than
did the FGFR4Gly388 allele [24] and was shown to promote
tumor progression through membrane type-1 matrix metal-
loproteinase-induced extracellular matrix degradation in-
volving the epithelial-to-mesenchymal transition at the
tumor/stromal border [25].
Point mutations are rare; however, they have been de-
tected in human breast tumors, including S125L in FGFR1
and R203C in FGFR2 [26]. An activating point mutation in
FGFR4 (Y367C), which causes constitutive receptor
dimerization and activation of MAPK, was identified in the
MDA-MB-453 breast cancer cell line [27].
Prognostic significance of FGFR aberrancy
Various studies have investigated the role of the FGFR
pathway as a predictive/prognostic marker, with several
suggesting that aberrant FGFR expression is associated
with an increased risk of breast cancer and is correlated
with a poor prognosis. For example, FGFR1 and FGFR2
are preferentially amplified in ER? breast cancer and
TNBC, respectively [28], and FGFR1 amplification was an
independent predictor of overall survival and poor outcome
in patients with ER? breast cancer [9, 29]. However, these
results may be confounded by other potential oncogenes on
8p11–12, which may also contribute [30–33]. Therefore,
amplification status of 8p11-12 may not be a sufficient
screening mechanism for clinical trials of FGFR-targeted
drugs. Other genes on different chromosomes may also
have an impact. For example, co-amplification of cyclin D1
(CCND1; chromosome 11) and FGFR1 were associated
with a significant reduction in patient survival [34].
The prognostic role of FGFR2 has also been reported.
Indeed, increased expression of FGFR2 is associated with
poor overall survival and disease-free survival [35]. Fol-
lowing the detection of FGFR2 and FGFR3 constitutive
activation in hormone-independent murine mammary tu-
mors, FGFR expression levels were determined in tumor
samples from patients with breast cancer (n = 58) [36].
This analysis detected a strong association between FGFR2
and FGFR3, with weaker associations between FGFR2 or
FGFR3 and ER. The study also found that FGFR4 ex-
pression correlated with human epidermal growth factor
receptor 2 (HER2) overexpression. Other studies have
shown that the FGFR2 SNPs rs2981582, rs1219648,
rs2420946, and rs2981579 were significantly associated
with an increased risk of breast cancer [37, 38]. Women
with all three SNPs had a 1.36-fold greater chance of
getting breast cancer than did those with no or no more
than two SNPs, and the risk was greater in women with
ER? and/or PR? cancer, premenopausal women, and
women who gave birth to their first child at a later age.
The FGFR4Arg388 allele has been correlated with sig-
nificantly reduced disease-free survival [23], and, in a
meta-analysis and pooled analysis of patients with cancer,
including breast, a significant association between the
FGFR4Arg388 allele and nodal involvement was identified
[39]. Additionally, carriers of the FGFR4Arg388 allele had
an increased hazard of poor overall survival compared with
carriers of the FGFR4Gly388 allele.
Role of FGFR in resistance mechanisms
Various studies support the role of the FGFR pathway in
endocrine resistance. For example, in patients with ER?
breast cancer treated with tamoxifen, high FGFR4 mRNA
levels were associated with poor clinical benefit and shorter
progression-free survival [40]. Additionally, evidence
suggests that resistance to HER2-targeted therapy may
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result from a switch in dependency on the ER/HER2 sig-
naling pathway to the FGFR signaling pathway [41]. In that
study, FGFR2 was highly amplified, FGFR2 was overex-
pressed, and HER2 expression was reduced in a lapatinib-
resistant cell line (UACC812/LR). The survival of
UACC812/LR cells appeared dependent on FGFR2, be-
cause inhibition of FGFR2 induced cell apoptosis.
Several studies suggest that FGFR signaling mediates re-
sistance to hormonal therapies through activation of the MAPK
and PI3K pathways. For example, in FGFR1-amplified breast
cancer cell lines, FGFR signaling caused persistent MAPK
activation followed by cyclin D1 expression, which led to ta-
moxifen resistance [13]. This activated signaling occurred in
both an ER-dependent and -independent manner, and the
FGFR1-induced tamoxifen resistance was reversible following
treatment with FGFR1-directed siRNA. Additionally, consti-
tutive activation of FGFR3 in MCF-7 cells reduced sensitivity
to tamoxifen in an ER-independent manner through stimulation
of the MAPK and PI3K pathways [42]. In this study, activation
of phospholipase Cc was critical for activation of MAPK and
PI3K and subsequently for tamoxifen resistance.
FGFR signaling may also mediate resistance to che-
motherapy in breast cancer. In patients with node-positive
breast cancer receiving chemotherapy as an adjuvant
therapy, presence of the FGFR4Arg388 allele was sig-
nificantly associated with poor disease-free survival and
overall survival [43]. Additionally, FGFR4 is upregulated
in MDA-MB-453 breast cancer cells that are resistant to
doxorubicin and cyclophosphamide, and FGFR4 overex-
pression leads to upregulation of the anti-apoptotic mole-
cule Bcl-xl through MAPK activation [27].
Targeting the FGFR pathway in preclinical studies
The evidence supporting a role of the FGFR pathway in
breast cancer has led to preclinical investigation of FGFR
pathway-targeting agents, and several approaches have
been explored. For example, FP-1039 is an FGF ligand trap
consisting of the extracellular domain of FGFR1 fused to
the Fc region of IgG [44]. In xenograft models using JIMT-
1, an FGFR1-amplified and -overexpressing cell line [13],
FP-1039 blocked tumor formation. In another approach,
monoclonal antibody GP369 targets the epithelial-ex-
pressed FGFR2-IIIb receptor isoform, whose overexpres-
sion can drive tumorigenesis [45, 46]. In a xenograft model
with MFM-223 breast cancer cells (a cell line with 287
genomic copies of FGFR2), GP369 induced tumor stasis.
More commonly, the FGFR pathway has been targeted
using small molecule inhibitors. SU5402, an FGFR1 small
molecule inhibitor, reduced cell survival in several breast
cancer cell lines; the sensitivity was greatest in MDA-MB-
134 cells [47].
PD173074 is a selective FGFR1 and FGFR3 inhibitor
that has shown activity in numerous breast cancer cell
lines. For example, it inhibited FGFR tyrosine kinase ac-
tivity and autophosphorylation and caused G1 growth ar-
rest in MDA-MB-415, MDA-MB-453, and SUM52 [48].
The study also showed that FGFR inhibition led to the
downregulation of cyclin D1/2 expression, inhibition of
cyclin D/cdk4 activity, and reduced pRB phosphorylation.
In the FGFR1-, FGFR2-, and FGFR3-expressing cell line
4T1, PD173074 demonstrated concentration-dependent
apoptosis, inhibited tumor growth and metastases to the
lung, and increased CD4 and CD8 T cell infiltration to the
spleen and tumors in xenograft models [49]. Other studies
have shown that PD173074 treatment inhibited MAPK and
PI3K/AKT signaling and induced cell-cycle arrest and
apoptosis in 47 % of TNBC cell lines and significantly
reduced the growth of CAL51 basal-like breast cancer cell
line-containing xenografts [15, 50]. Finally, decreased
phosphorylation of FGFR2 and induction of apoptosis was
observed in a lapatinib-resistant breast cancer cell line
(UACC812/LR) following treatment with PD173074 [41].
Brivanib alaninate (BMS-582664) inhibits VEGFR2,
VEGFR3, and FGFR3 (and to a lesser extent FGFR1 and
FGFR2) [51] and has caused decreased receptor au-
tophosphorylation, inhibited FGF2-induced tyrosine kinase
activity, and reduced phosphorylation of ERK and AKT in
breast cancer cell lines with amplification of FGFR1 [52].
Additionally, brivanib inhibited the growth of human
H3396 breast-tumor xenografts [53] and elicited tumor
growth regression in tamoxifen-sensitive (MCRF-7 E2)
and tamoxifen-stimulated (MCF-7 Ral, MCF-7 Tam)
breast cancer cell lines [54].
Lucitanib (E-3810)—a small molecule inhibitor of
VEGFR1-3, FGFR1-2, and colony stimulating factor 1
receptor—has demonstrated anti-angiogenic and anti-tu-
mor activity in preclinical models [55]. Additionally, in
combination with paclitaxel, lucitanib caused long-lasting
tumor regressions in xenografts of the TNBC cell line
MDA-MB-231 [56].
Dovitinib (TKI258) is a small molecule inhibitor of
FGFR1-3, VEGFR1-3, c-KIT, fms-related tyrosine kinase
3 (FLT3), platelet-derived growth factor receptor (PDGFR)
b, c-KIT, and FLT3 [57]. In 4T1 and the FGFR2- and
FGFR3-expressing cell line 67NR, dovitinib decreased
FGFR substrate 2 (FRS2) phosphorylation; decreased the
activity of ERK1/2, AKT, and phospholipase Cc; and
blocked proliferation [58]. Dovitinib also significantly re-
duced primary tumor outgrowth in xenograft models with
these cell lines and reduced tumor-induced lung metastasis
in the 4T1 model [58]. In other tumor models using these
cell lines, combining dovitinib with the PI3K/mTOR in-
hibitor BEZ235 or the pan-ErbB inhibitor AEE788 blocked
the FGFR/FRS2/Erk and PI3K/Akt/mTOR pathways and
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further inhibited tumor growth and blocked tumor spread
[59]. In experiments with FGFR-amplified cell lines,
dovitinib decreased pFRS2 and pERK/MAPK and inhib-
ited cell growth in MDA-MB-134 (FGFR1-amplified) and
SUM52 (FGFR2-amplified) lines [60]. Furthermore, dovi-
tinib caused tumor regressions in HBCx-2 (8 FGFR1
copies) and HBCx-3 (10 FGFR2 copies) xenograft models.
ACTB-1003—a multitargeted kinase inhibitor of
FGFR1, VEGFR2, Tie-2, RSK, and p70S6K—demon-
strated potent, low nanomolar activity in a variety of tumor
models, including breast cancer [61]. Ponatinib, an oral
multitargeted kinase inhibitor of Bcr-Abl as well as
FGFR1-4 [62–64], inhibited cell growth in MDA-MB-134
and SUM52PE and in MFM-223—a cell line that also has
FGFR2 amplification [65].
Clinical trials with FGFR pathway-targeting agents
in breast cancer
Data from the various preclinical studies clearly demon-
strate the role of the FGFR pathway in breast cancer and
have led to clinical trials exploring patients who may best
benefit from targeted treatments (Table 1). Indeed, many of
the clinical trials testing FGFR tyrosine kinase inhibitors in
breast cancer are requiring molecular prescreening prior to
study entry to enable correlation between response and
FGFR pathway activation or are only enrolling patients
with FGFR pathway activation.
In a phase 2 trial of dovitinib (NCT00958971), patients
with metastatic HER2- breast cancer were grouped based on
hormone receptor (HR) status and FGFR1 amplification (as
assayed by silver in situ hybridization) [60]. Dovitinib was
reasonably well tolerated in the heavily pretreated patients
(n = 81), and unconfirmed partial response and/or stable
disease at C24 weeks were observed in 25 % of the 20
evaluable patients with HR? FGFR1-amplified breast cancer
(3 % in the 31 evaluable patients with FGFR1 nonamplified,
HR- disease). In preplanned analyses, amplifications of
FGFR1/2 by quantitative polymerase chain reaction (PCR)
were found to be associated with anti-tumor activity in pa-
tients with HR?. These data led to the initiation of a phase 2
study of dovitinib in combination with fulvestrant in post-
menopausal patients with locally advanced or metastatic
HER2-, HR? breast cancer who have progressed during or
following endocrine therapy (NCT01528345) [66]. Of in-
terest, the study requires molecular prescreening prior to
study entry, with patients grouped based on FGFR pathway
amplification status (FGFR1, FGFR2, or FGF3 by quanti-
tative PCR). Additional ongoing studies include a phase 2
study of dovitinib as salvage therapy in patients with re-
lapsed stage IV HER2- inflammatory breast cancer
(NCT01262027) and a phase 1/2 study of dovitinib in
combination with aromatase inhibitors in patients with
metastatic breast cancer with evidence of resistance to prior
aromatase inhibitor therapy (NCT01484041). The latter
study also requires tumor availability for determination of
FGFR1 amplification for study inclusion.
AZD4547 is an inhibitor of FGFR1-3 and VEGFR2 [67]. A
phase 1/2 study of AZD4547 in combination with the estrogen
receptor antagonist fulvestrant in patients with ER? breast
cancer with high levels of FGFR1 is currently ongoing
(NCT01202591). Tumor biopsy must be available to confirm
FGFR1 polysomy or amplification for study inclusion. Another
ongoing phase 1/2 study is comparing AZD4547 in combination
with letrozole or anastrozole versus exemestane in patients with
ER? breast cancer who relapsed during adjuvant endocrine
therapy with anastrozole or letrozole (NCT01791985). Enroll-
ment in the expansion phase of this study requires tumor biopsy
for confirmation of FGFR1 status by fluorescence in situ hy-
bridization (FISH). Additionally, an ongoing phase 2 study is
evaluating AZD4547 in patients with FGFR1- or FGFR2-am-
plified tumors (NCT01795768) [68]. Patients with breast cancer
must have FGFR1 amplification and are required to provide
archival or fresh tumor biopsy for confirmation of FGFR am-
plification, with a second biopsy planned on days 10–14.
A phase 1/2 study testing lucitanib in patients with ad-
vanced solid tumors is currently ongoing (NCT01283945)
[69]. In dose expansion, patients with FGFR1 or 11q12-14
amplification per FISH or comparative genomic hy-
bridization array were enrolled; of nine evaluable patients
with breast cancer, four achieved PR sustained over four to
six courses, three achieved stable disease, and two had
progressive disease [70]. A phase 2 study of lucitanib is
also ongoing in patients with ER? FGFR1-amplified and
-nonamplified metastatic breast cancer (NCT02053636).
The pan-FGFR inhibitor BGJ398 is being tested in pa-
tients with tumors containing FGFR1 or FGFR2 amplifi-
cations or FGFR3 mutations (NCT01004224). In this
study, reductions in tumor volume were observed with
single-agent BGJ398 in some patients with breast cancer
[71]. BGJ398 is also being studied in a phase 1b trial in
combination with the a-selective PI3K inhibitor BYL719
in patients whose tumors have PIK3CA mutations and
FGFR1-3 alterations (NCT01928459).
In a dose-escalation study, the pan-FGFR inhibitor JNJ-
42756493 also demonstrated reductions in tumor volume in a
patient with breast cancer (NCT01962532) [72]. In a second
phase 1 trial in patients with advanced or refractory solid
tumors or lymphoma, the dose-expansion phase will include
a cohort of patients with breast cancer with FGFR1, FGFR2,
or FGFR4 gene amplifications (NCT01703481).
Other FGFR-targeted agents have been explored in
clinical trials, but without requiring FGFR testing at study
entry. For example, orantinib (TSU-68)—an inhibitor of
VEGFR2, PDGFR, and FGFR—had no activity as a single
4 Breast Cancer Res Treat (2015) 150:1–8
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agent in patients with metastatic breast cancer progressing
despite treatment with a prior anthracycline-containing
regimen and taxane [73]. However, in patients with an-
thracycline resistance, orantinib in combination with
docetaxel achieved an overall response rate of 21 % [74].
Additional ongoing studies not requiring FGFR testing at
entry include a study of brivanib alaninate in combination
with chemotherapy in patients with advanced cancer
(NCT00798252) and a study of docetaxel with or without
nintedanib (BIBF 1120)—an inhibitor of FGFR1-3,
VEGFR1-3, PDGFRa, PDGFRb, and FLT3 [75]—as sec-
ond-line chemotherapy in patients with HER2- metastatic
or locally recurrent breast cancer (NCT01658462).
Bioassays
Challenges remain in identifying the patient population that
may benefit from FGFR pathway-targeted therapy. For ex-
ample, definitions of FGFR pathway amplification vary both
Table 1 Breast cancer clinical trials of FGFR pathway-targeting agents





Dovitinib in FGFR1-amplified and -nonamplified metastatic or
advanced HER2- breast cancer [60]
2 NCT01528345
ongoing
Dovitinib ? fulvestrant in HR?/HER2- LA/mBC following
progression on or after endocrine therapy [66]
2 NCT01262027
ongoing




Dovitinib ? aromatase inhibitor in HR?/HER2- mBC
resistant to an aromatase inhibitor
AZD4547 FGFR1-3, VEGFR2 1/2 NCT01202591 active
(not recruiting)
AZD4547 ? fulvestrant vs fulvestrant alone in ER? breast
cancer with FGFR1 polysomy or gene amplification
following progression after endocrine therapy
1/2 NCT01791985
ongoing
AZD4547 ? (anastrozole or letrozole) versus exemestane in
ER? breast cancer progressing on anastrozole or letrozole
2 NCT01795768
ongoing
AZD4547 in patients with FGFR1- or FGFR2-amplified
tumors (including HER2-, FGFR1-amplified LA/mBC) [68]
Lucitanib FGFR1, VEGFR1-3, CSF1R 1/2 NCT01283945
ongoing
Lucitanib in patients with advanced solid tumors (including, in
dose expansion, FGFR1-amplified breast cancer with at least
one prior chemotherapy or at least one prior endocrine
therapy if ER?) [69, 70]
2 NCT02053636
ongoing
Lucitanib in FGFR1-amplified or -nonamplified ER? mBC
BGJ398 FGFR1-4 1 NCT01004224
ongoing
BGJ398 in patients with advanced solid tumors with FGFR1 or
FGFR2 amplification or FGFR3 mutation
1 NCT01928459
ongoing
BGJ398 ? BYL719 in solid tumors (including mBC with
PIK3CA mutations and FGFR1-3 alterations)
JNJ-42756493 FGFR1-4 1 NCT01703481
ongoing
JNJ-42756493 in patients with advanced or refractory solid
tumors or lymphoma (includes a cohort with breast cancer)
1 NCT01962532
ongoing
JNJ-42756493 in patients with advanced or refractory solid
tumors or lymphoma (includes a cohort with FGFR-
amplified, -mutated, or -translocated breast cancer)
Orantinib FGFR1, VEGFR2, PDGFRb 2 NR Orantinib in patients with mBC progressing despite prior
anthracycline-containing regimen and taxane [73]
2 NR Orantinib ? docetaxel in mBC patients with anthracycline
resistance [74]
Brivanib FGFR3, VEGFR2, VEGFR3 1 NCT00798252 active
(not recruiting)









Neoadjuvant paclitaxel versus nintedanib followed by
nintedanib ? paclitaxel in early HER2- breast cancer
CSF1R colony stimulating factor 1 receptor, ER estrogen receptor, FGFR fibroblast growth factor receptor, FLT3 fms-related tyrosine kinase 3,
HER2 human epidermal growth factor receptor 2, HR hormone receptor, LA/mBC locally advanced or metastatic breast cancer, NR not registered,
PDGFR platelet-derived growth factor receptor, VEGFR vascular endothelial growth factor receptor
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in the methods used and the threshold copy number. For ex-
ample, amplicons may not accurately reflect the level of am-
plification of the component genes and be confounded by
other potential oncogenes in the amplicon. Additionally,
measurement of gene amplification may not reflect protein
expression or activity. Conversely, detection of activating
mutations may not be relevant unless the gene is expressed.
The best method is yet unknown, but analyses comparing
screening methods with efficacy can be informative. For ex-
ample, in a phase 2 study with dovitinib, tumor reduction was
greater in patients with FGF pathway amplification identified
by quantitative PCR than in those with FGF pathway ampli-
fication identified by in situ hybridization [60]. However, no
consensus has been reached, and ongoing trials are using
different methods for detecting FGFR pathway activation/
aberration, which will complicate cross-study data interpre-
tation. Careful analyses of the biomarker data from clinical
trials may improve the ability to identify the optimal patient
population that will benefit from FGFR-targeted therapies.
Conclusions
The FGFR pathway is involved in multiple cellular pro-
cesses, and research has shown that aberrant pathway am-
plification is observed in multiple tumor types, including
breast cancer. As research advances toward targeted treat-
ment of cancer, it is increasingly important to understand
how the FGFR pathway is driving the disease and, more
importantly, how it can be targeted. Multiple agents that
target FGFR pathway components are being investigated.
Results from these trials are also expected to help refine our
ability to identify patients with FGFR pathway-amplified
tumors who may best respond to these treatments.
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